Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation‐mediated hepatocarcinogenesis

Chronic inflammation is strongly associated with an increased risk for hepatocellular carcinoma (HCC) development. The multidrug resistance 2 (Mdr2)–knockout (KO) mouse (adenosine triphosphate–binding cassette b4−/−), a model of inflammation‐mediated HCC, develops chronic cholestatic hepatitis at an early age and HCC at an adult age. To delineate factors contributing to hepatocarcinogenesis, we compared the severity of early chronic hepatitis and late HCC development in two Mdr2‐KO strains: Friend virus B‐type/N (FVB) and C57 black 6 (B6). We demonstrated that hepatocarcinogenesis was significantly less efficient in the Mdr2‐KO/B6 mice versus the Mdr2‐KO/FVB mice; this difference was more prominent in males. Chronic hepatitis in the Mdr2‐KO/B6 males was more severe at 1 month of age but was less severe at 3 months of age in comparison with age‐matched Mdr2‐KO/FVB males. A comparative genome‐scale gene expression analysis of male livers of both strains at 3 months of age revealed both common and strain‐specific aberrantly expressed genes, including genes associated with the regulation of inflammation, the response to oxidative stress, and lipid metabolism. One of these regulators, galectin‐1 (Gal‐1), possesses both anti‐inflammatory and protumorigenic activities. To study its regulatory role in the liver, we transferred the Gal‐1–KO mutation (lectin galactoside‐binding soluble 1−/−) from the B6 strain to the FVB strain, and we demonstrated that endogenous Gal‐1 protected the liver against concanavalin A–induced hepatitis with the B6 genetic background but not the FVB genetic background. Conclusion: Decreased chronic hepatitis in Mdr2‐KO/B6 mice at the age of 3 months correlated with a significant retardation of liver tumor development in this strain versus the Mdr2‐KO/FVB strain. We found candidate factors that may determine strain‐specific differences in the course of chronic hepatitis and HCC development in the Mdr2‐KO model, including inefficient anti‐inflammatory activity of the endogenous lectin Gal‐1 in the FVB strain. (HEPATOLOGY 2013 )

[1]  Carol J. Bult,et al.  Mouse Phenome Database , 2013, Nucleic Acids Res..

[2]  P. Borst,et al.  Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.

[3]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[4]  D. Figeys,et al.  Lipin - The bridge between hepatic glycerolipid biosynthesis and lipoprotein metabolism. , 2010, Biochimica et biophysica acta.

[5]  G. Rabinovich,et al.  Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1. , 2011, Molecular immunology.

[6]  R. Lechler,et al.  Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. , 2007, Blood.

[7]  E. Robertson,et al.  Normal development of mice carrying a null mutation in the gene encoding the L14 S-type lectin. , 1993, Development.

[8]  H. Yang,et al.  Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[9]  R. Kiss,et al.  Galectin-1: a small protein with major functions. , 2006, Glycobiology.

[10]  Y. Kloog,et al.  Galectin-1 Augments Ras Activation and Diverts Ras Signals to Raf-1 at the Expense of Phosphoinositide 3-Kinase* , 2002, The Journal of Biological Chemistry.

[11]  R. Zechner,et al.  Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. , 2012, Gastroenterology.

[12]  Wen Tan,et al.  Daintain/AIF‐1 promotes breast cancer proliferation via activation of the NF‐κB/cyclin D1 pathway and facilitates tumor growth , 2008, Cancer science.

[13]  Eytan Domany,et al.  Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. , 2006, Cancer research.

[14]  R. Maronpot.  Biological Basis of Differential Susceptibility to Hepatocarcinogenesis among Mouse Strains , 2009, Journal of toxicologic pathology.

[15]  F. Corrales,et al.  S-Adenosylmethionine revisited: its essential role in the regulation of liver function. , 2002, Alcohol.

[16]  F. Kuipers,et al.  Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. , 1998, Gastroenterology.

[17]  G. Servillo,et al.  Galectin‐1 exerts immunomodulatory and protective effects on concanavalin a–induced hepatitis in mice , 2000, Hepatology.

[18]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[19]  M. Shipp,et al.  Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma , 2012, The Journal of experimental medicine.

[20]  H. Glatt,et al.  Human cytochrome P450 reductase can act as a source of endogenous oxidative DNA damage and genetic instability. , 2006, Free radical biology & medicine.

[21]  Y. Hayashizaki,et al.  T2BP, a novel TRAF2 binding protein, can activate NF-kappaB and AP-1 without TNF stimulation. , 2002, Biochemical and biophysical research communications.

[22]  Yaohong Zhu,et al.  TFF3 modulates NF-κB and a novel negative regulatory molecule of NF-κB in intestinal epithelial cells via a mechanism distinct from TNF-α , 2005 .

[23]  Y. Shiloh,et al.  Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks , 2010, Proceedings of the National Academy of Sciences.

[24]  D. Lane,et al.  HEXIM1 and the Control of Transcription Elongation: From Cancer and Inflammation to AIDS and Cardiac Hypertrophy , 2007, Cell cycle.

[25]  E. Domany,et al.  Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice , 2007, Molecular Cancer Therapeutics.

[26]  I. Rusyn,et al.  Interstrain differences in liver injury and one‐carbon metabolism in alcohol‐fed mice , 2012, Hepatology.

[27]  Luigi Tornillo,et al.  Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness , 2010, Molecular medicine.

[28]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[29]  M. F. Troncoso,et al.  Novel roles of galectin‐1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth , 2011, Hepatology.

[30]  K. Zatloukal,et al.  Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model , 2012, Laboratory Investigation.

[31]  Ruud P. M. Dings,et al.  Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy , 2006, Proceedings of the National Academy of Sciences.

[32]  Eric E Schadt,et al.  Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. , 2009 .

[33]  Eytan Domany,et al.  Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice , 2007, Molecular Cancer Research.

[34]  A. Groen,et al.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. , 1994, The American journal of pathology.

[35]  P. Collins,et al.  Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model. , 2010, Cancer letters.

[36]  A. Ryo,et al.  Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. , 2003, International journal of oncology.